The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
about
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortalityOptimizing antibiotic therapy in the intensive care unit setting.Prior antimicrobial therapy in the hospital and other predisposing factors influencing the usage of antibiotics in a pediatric critical care unitBench-to-bedside review: antimicrobial utilization strategies aimed at preventing the emergence of bacterial resistance in the intensive care unit.Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatmentThe ADP-ribosyltransferase domain of the effector protein ExoS inhibits phagocytosis of Pseudomonas aeruginosa during pneumoniaEvaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparatorsInadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients.Inadequate treatment of ventilator-associated and hospital-acquired pneumonia: risk factors and impact on outcomesPrognostic factors in severe community-acquired pneumonia in patients without co-morbid illness.The pulmonary physician in critical care * 4: Nosocomial pneumonia.De-escalation antimicrobial chemotherapy in critically III patients: pros and cons.Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study.Accuracy of tracheal aspirate gram stain in predicting Staphylococcus aureus infection in ventilator-associated pneumoniaImpact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay.Therapy of ventilator-associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy".Comparing influence of intermittent subglottic secretions drainage with/without closed suction systems on the incidence of ventilator associated pneumonia.Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.A pilot study of the noninvasive assessment of the lung microbiota as a potential tool for the early diagnosis of ventilator-associated pneumoniaImpact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia.De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unitBacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study.Ventilator-associated pneumonia in a multi-hospital system: differences in microbiology by location.Postoperative complications after thoracic surgery in the morbidly obese patient.The Role of ExoS in Dissemination of Pseudomonas aeruginosa during Pneumonia.Nosocomial pneumonia in the intensive care unit: controversies and dilemmas.A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill PatientsTreating serious infections: focus on cefepime.Severe Pseudomonas aeruginosa infections. Tackling the conundrum of drug resistance.Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.Combination therapy for treatment of infections with gram-negative bacteria.Defining the need for new antimicrobials: clinical and economic implications of resistance in the hospitalised patient.Management of severe bacterial infections.Role of linezolid in the treatment of complicated skin and soft tissue infections.Ventilator-associated pneumonia: a review.Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of conceptEmpirical Antibiotic Therapy for Ventilator-Associated Pneumonia.Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study
P2860
Q24530412-0B397AC7-46B1-4997-8EA6-DF5FDBFFBB63Q24796204-98DCF182-C8D3-496B-BD48-DF07BA13A95BQ24803615-F53093EA-1ECD-4AFF-B953-861296C828C1Q24813204-08D0E2A8-5DEE-48AD-89FB-690537620C0BQ33722082-B07E1310-F781-4C9F-925A-9FA867014583Q33751840-ECD7ED66-67D1-4CF7-97FF-2C3B349B329CQ33770046-93B5CEB8-0B95-4C7A-87EA-CC24EC24F890Q34026240-20A4ABF7-7B92-44D7-AC7E-174909DF888CQ34026818-A8512FF4-E236-4A75-ABDE-8A78CED82CC0Q34052619-9109C5CC-F4D2-462A-A4DB-E79ED310BFC1Q34457254-498C381A-4D44-4D5A-A282-C7F8317EFEB2Q34530347-57719D33-0415-484B-8132-85961C03E184Q34581869-9DF6CBD7-24C8-4129-9B00-EB139FC2AF80Q34590045-3CF85C33-0D83-4CD1-B86B-0420ED0026C5Q34999543-02CB2917-54F9-49E9-9B9E-700BD8B55577Q35068268-8643D2B0-4121-4769-BE05-B19544978F19Q35091494-C3580F1A-1DE2-4148-B6A6-C3E9667B1A0DQ35099758-0EB06C3E-9DD7-4A5D-8DAF-203321F96DC7Q35307056-21B155E2-0730-4973-969C-2AF43739F287Q35356144-E8EBB1D9-6A2A-4631-BC58-FC6ACEBEC95BQ35489569-F9C89071-3D5A-4F58-A20C-C865ECE9BBFEQ35559358-929C470D-5C59-4126-BFA9-7B8582B30460Q35561279-6201BF98-2484-4B5E-A601-FB90F1B6C160Q35567016-079D12E0-8935-487C-B424-668F3A8FF04EQ35597912-09AA0203-52B3-43E9-B847-36BF16B01D04Q35661513-53A18571-CFCC-4123-A953-98D06DFBB2F3Q35668315-7CAF65DD-E316-4D87-AFB5-8395A631C4E2Q35702259-DA3FE3BB-B2A6-468B-94B8-E9E3CA8B5B7CQ35860038-9ADFD582-16B2-4E87-AADD-91A1008EE1DDQ35976856-626F780F-7DB5-4789-9B92-437AF9CA9EF8Q36021050-ECB16025-0B51-4FBD-97F3-EAF885FF70DCQ36095101-43FD176D-811B-437C-84B5-7FD5441C57CBQ36156077-7ECB5F31-AD6D-4DAB-AF3F-9390BE8B79E7Q36161246-487FCD30-5550-4D25-BBC7-463E89F62951Q36233511-3589E86E-2269-4A6F-9C7E-0108379410A9Q36505478-9441BF8B-D443-4061-8816-56CC3FDC3CE9Q36541263-D53FD0F0-3E6D-4CB5-8674-BDE93BDC70B4Q36633627-10CAC545-AB27-499D-867F-9E04C6D62E40Q36683419-87881714-4B49-4996-956F-58B436B0FC37Q36880729-6131082B-C1D8-4643-998C-6802E1EF18E2
P2860
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
description
im Juli 1997 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 1997
@uk
name
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
@en
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
@nl
type
label
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
@en
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
@nl
prefLabel
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
@en
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
@nl
P2093
P2860
P1476
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
@en
P2093
DOLORS MARISCAL
JORDI VALLES
MIGUEL GALLEGO
ROSARIO SOÑORA
P2860
P304
P356
10.1164/AJRCCM.156.1.9607030
P407
P50
P577
1997-07-01T00:00:00Z